Entera Bio names Riccardo Camisasca as chief medical officer
The appointment, effective immediately, comes ahead of the company's planned Phase 3 start for its lead osteoporosis candidate EB613.
SEC filing
Latest
5 stories
Tuesday, August 18
Wednesday, August 12
Entera Bio reports $274.99 million offering completed under Form D
The Israel-based biotechnology company sold ordinary shares and pre-funded warrants to 53 investors in a private placement relying on Rule 506(b).
SEC filing
Friday, August 7
Entera Bio reports Q2 2026 results, cites FDA alignment on EB613 Phase 3 design
Entera raised $275 million in a private placement led by BVF Partners to fund a registrational Phase 3 trial of its oral osteoporosis drug EB613 through NDA submission.
SEC filing
Tuesday, July 28
Entera Bio raises $275 million in private placement led by BVF Partners funds
The Israeli drug developer will use the proceeds to launch a phase 3 osteoporosis trial of EB613 after closing the deal on July 28, 2026.
SEC filing
Thursday, July 16
Entera Bio holds annual meeting, expands share pool and authorized shares
The July 14, 2026 meeting produced shareholder approval for three directors, an equity plan increase, and a near 2.5-fold rise in authorized shares.
SEC filing